Skip to main content

CARA

Stock
Health Care
Biotechnology

Performance overview

CARA Price
Price Chart

Forward-looking statistics

Beta
2.17
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Company info

SectorHealth Care
IndustryBiotechnology
Employees76
Market cap$34.1M

Fundamentals

Enterprise value$30.9M
Revenue$7.1M
Revenue per employee—
Profit margin91.31%
Debt to equity-9.68

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$46.59
Dividend per share—
Revenue per share$4.69
Avg trading volume (30 day)$126K
Avg trading volume (10 day)$267K
Put-call ratio—

Macro factor sensitivity

Growth-1.7
Credit+8.8
Liquidity+2.1
Inflation-5.1
Commodities-3.2
Interest Rates-3.4

Valuation

Dividend yield0.00%
PEG Ratio-6.91
Price to sales1.14
P/E Ratio-6.91
Enterprise Value to Revenue4.33
Price to book—

Upcoming events

Next earnings dayNovember 15, 2024
Next dividend day—
Ex. dividend day—

News

These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'

Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.

Benzinga (June 13, 2024)
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates

Cara Therapeutics (CARA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.49 per share a year ago.

Zacks Investment Research (May 13, 2024)
Cara Therapeutics stock sinks on larger-than-expected Q4 earnings miss

Yahoo Finance Live anchors Julie Hyman and Jared Blikre discuss fourth-quarter earnings for Cara Therapeutics.

Yahoo Finance (March 7, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free